Science News
from research organizations

Original cell type does not affect iPS cell differentiation to blood

New molecular markers for stable iPS cell differentiation to hematopoietic cells

Date:
July 28, 2016
Source:
Center for iPS Cell Research and Application - Kyoto University
Summary:
The effectiveness of reprogramming cells into blood cells is thought to depend on the original cell type and reprogramming method. Researchers show this assumption is actually the result of epigenetic effects, suggesting any founder cell and reprogramming method is feasible for blood production.
Share:
FULL STORY

The type of found cell is thought to influence the efficiency of iPS cell differentiation to blood cells, with blood founder cells being best. CiRA researchers show, however, that methylation (yellow balls) is the real culprit, and that blood methylation is lower than other founder cells.
Credit: Masaya Todani, CiRA

Cell reprogramming involves making one cell type into another. In theory, all cells can be reprogrammed, but there is evidence that the original cell (founder cell) influences the type of cell to which it can be reprogrammed. In general, founder cells are easy to acquire from a donor and come in one of four types: fibroblasts, keratinocytes, peripheral and umbilical cord blood, and dental pulp cells. Labs from around the world have made iPS cell lines using different founder cells. The potential influence of founder cells is profound for regenerative medicine and other medical applications, since they suggest that the cell line should be selected based on the desired cell type.

Another factor that could also contribute to the efficiency of iPS cell line differentiation is the method with which the iPS cells were made. Many methods are used, but the most common, according to Associate Professor Yoshinori Yoshida at CiRA are "retrovirus, episomal plasmids and Sendai virus."

Blood describes a diverse group of cells that includes those that carry oxygen, heal wounds, and fight off infection, and the production of clinical grade blood has remained a major goal of reprogramming science. Some scientists have argued that to acquire hematopoietic cells, the best founder cells are coincidently hematopoietic cells. To investigate the contribution of founder cells in cell differentiation to hematopoietic cells, the Yoshida lab investigated an unprecedented number of iPS cell lines made using all of the above founder cells and reprogramming methods. .

Interestingly, the group found neither of these factors has a significant effect. Instead, they show the expression of certain genes and DNA methylations were better indicators of the efficiency at which a cell line could be differentiated into the hematopoietic lineage. "We found the IFG2 gene marks the beginning of reprogramming to hematopoietic cells," said Dr. Masatoshi Nishizawa, a hematologist in the Yoshida lab and first author of the new study. The researchers show that higher expression of the growth hormone IFG2, or insulin-like growth factor 2, is indicative of iPS cells initiating their conversion into hematopoietic cells. Even though IFG2 itself is not directly related to hematopoiesis, its uptake corresponded to an increase in the expression of genes that are.

Although IFG2 marked the beginnings of differentiation to hematopoietic lineage, the completion of differentiation was marked by the methylation profiles of the iPS cell DNA. "DNA methylation has an effect on a cell staying pluripotent or differentiating," explained Associate Professor Yoshida. The completion of differentiation correlated with less aberrant methylation during the reprogramming process. Blood founder cells showed a much lower propensity for aberrant methylation than did other founder cells, which could explain why in the past scientists attributed the founder cell to the effectiveness of differentiating iPS cells to the hematopoietic lineage.

These findings reveal molecular factors that can be used to evaluate the differentiation potential of different cell lines, which should expedite the progress of iPS cells to clinical use. Nishizawa expects this work to act as a basis to evaluate cell lines for the preparation of other cell types. "I think each cell type will have its own special patterns," he said.


Story Source:

Materials provided by Center for iPS Cell Research and Application - Kyoto University. Note: Content may be edited for style and length.


Journal Reference:

  1. Masatoshi Nishizawa, Kazuhisa Chonabayashi, Masaki Nomura, Azusa Tanaka, Masahiro Nakamura, Azusa Inagaki, Misato Nishikawa, Ikue Takei, Akiko Oishi, Koji Tanabe, Mari Ohnuki, Hidaka Yokota, Michiyo Koyanagi-Aoi, Keisuke Okita, Akira Watanabe, Akifumi Takaori-Kondo, Shinya Yamanaka, Yoshinori Yoshida. Epigenetic Variation between Human Induced Pluripotent Stem Cell Lines Is an Indicator of Differentiation Capacity. Cell Stem Cell, 2016 DOI: 10.1016/j.stem.2016.06.019

Cite This Page:

Center for iPS Cell Research and Application - Kyoto University. "Original cell type does not affect iPS cell differentiation to blood: New molecular markers for stable iPS cell differentiation to hematopoietic cells." ScienceDaily. ScienceDaily, 28 July 2016. <www.sciencedaily.com/releases/2016/07/160728143305.htm>.
Center for iPS Cell Research and Application - Kyoto University. (2016, July 28). Original cell type does not affect iPS cell differentiation to blood: New molecular markers for stable iPS cell differentiation to hematopoietic cells. ScienceDaily. Retrieved May 28, 2017 from www.sciencedaily.com/releases/2016/07/160728143305.htm
Center for iPS Cell Research and Application - Kyoto University. "Original cell type does not affect iPS cell differentiation to blood: New molecular markers for stable iPS cell differentiation to hematopoietic cells." ScienceDaily. www.sciencedaily.com/releases/2016/07/160728143305.htm (accessed May 28, 2017).

RELATED STORIES